Kala Pharmaceuticals to Present at Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. BABA
7. AVGO
8. SPCX
9. HD
10. BJ

Get Alerts KALA Hot Sheet

Price: $0.82 -2.38%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

WALTHAM, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that Mark Iwicki, Chairman and Chief Executive Officer, will provide a corporate overview at the Bank of America Merrill Lynch 2018 Health Care Conference and the Jefferies 2018 Global Healthcare Conference. Details of the presentations are as follows:

Bank of America Merrill Lynch 2018 Health Care ConferenceDate: Tuesday, May 15, 2018Time: 11:35 AM PTLocation: Las Vegas, NV

Jefferies 2018 Global Healthcare ConferenceDate: Tuesday, June 5, 2018Time: 9:00 AM ETLocation: New York, NY

To access a live webcast and subsequent archived recording of the presentation, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.